Project Grant R01CA296974
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$445K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
The University of California, San Diego (UCSD) was awarded a $592,500 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, titled "MUTANT DNA-ACTIVATED KILLING SYSTEM FOR PRECISION BREAST CANCER THERAPY", will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. The research, to be conducted from February 1, 2025...
The federal Project Grant award, totaling $532,916, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research initiatives at the University of California, San Diego (UCSD) focused on "COMBINED EPIGENETIC REPROGRAMMING AND IMMUNOTHERAPY TO TACKLE HIGH-RISK MULTIPLE MYELOMA." The project aims to explore innovative approaches to disease prevention, diagnosis, treatment, and...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $2,186,372 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of California, Irvine (UCI) to support a 5-year research program investigating "tipping points" in cancer initiation and progression. The program will leverage mouse models to study stochastic, non-genetic cellular transitions and cell-cell interactions that drive the progression from pre-malignant to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $159,500.00 to the University of California, San Diego to investigate the molecular mechanisms underlying the initiation of heterochromatin, a tightly packed form of DNA essential for genome stability and tumor suppression. The key focus is on understanding the interplay between heterochromatin protein 1 (HP1) and the signal transducer and activator of transcription...
The University of California, Irvine received a $667,379 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to conduct research aimed at decoding the mechanisms of polyadenylation and its role in health and disease. The overarching goal is to develop a "poly(A) code" that can predict how DNA sequence impacts mRNA processing efficiency and drug sensitivity, which will help identify disease-causing genetic variants. This will involve applying...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), is providing $344,111 to Loyola University of Chicago to conduct research on targeting panoptotic pathways for the treatment of myelodysplastic syndromes (MDS). The primary objectives are to investigate whether inhibition of RIPK1 and TBK1 can prevent MDS and eliminate mutant hematopoietic stem/progenitor cells, thereby restoring blood cell counts and preventing...
The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), has awarded a $683,472 Project Grant to the University of Cincinnati to advance pharmacodynamically directed targeted therapy for acute myeloid leukemia (AML). The 5-year project aims to transition the DHODH inhibitor HOSU-53 into clinical trials, starting with a Phase 1 trial in 2025 to evaluate the compound's pharmacokinetics, pharmacodynamics, and ability to eliminate specific AML cell clones....
The University of California, San Diego (UCSD) was awarded a $551,207.00 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to research a new therapeutic target to prevent pancreatic cancer metastasis. The 3-year grant period runs from July 1, 2023 to June 30, 2026. The project aims to investigate medical solutions for the battlefield by transforming health care through innovative and impactful research in areas like cancer...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the University of California, San Diego (UCSD) to develop slow-release CPMV (Cowpea Mosaic Virus)-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to formulate CPMV-laden slow-release devices, establish and tune the release rates, confirm the structural integrity and biological activity of the released CPMV, and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports fundamental research aimed at understanding the biological mechanisms underlying acute myeloid leukemia (AML) development and progression. The $487,973 award to The Leland Stanford Junior University will fund a 5-year project investigating the role of pre-leukemic hematopoietic stem cells (pHSCs) in AML pathogenesis. The research will explore the clonal evolution, kinetics, and cell...